How do Celexa and Lexapro differ chemically?
Celexa (citalopram) and Lexapro (escitalopram) are both selective serotonin reuptake inhibitors (SSRIs) used to treat depression and anxiety. Escitalopram is the S-enantiomer of citalopram, a purified active form from the racemic mixture of citalopram, which contains both S- and R-enantiomers. This makes Lexapro more targeted, potentially reducing inactive components.[1]
What are the key differences in dosing and effectiveness?
Lexapro typically requires lower doses for similar effects—10-20 mg daily versus Celexa's 20-40 mg—due to its higher potency from the active isomer. Clinical studies show Lexapro may have a faster onset and slightly better remission rates in major depressive disorder (8-12 weeks), though head-to-head trials indicate comparable overall efficacy.[1][2]
Which has more side effects, and why?
Both share common SSRI side effects like nausea, insomnia, sexual dysfunction, and fatigue. Celexa carries a higher risk of dose-dependent QT prolongation (heart rhythm issues), leading to an FDA maximum dose of 40 mg (20 mg for those over 60 or with liver issues). Lexapro has a lower QT risk at standard doses up to 20 mg. Lexapro may cause fewer overall adverse events in some analyses.[2][3]
How do costs and availability compare?
Lexapro, launched later (2002 vs. Celexa's 1998), entered the generic market in 2012, making both affordable generics today. Generic escitalopram often costs less per dose than generic citalopram due to simpler manufacturing, but prices vary by pharmacy (e.g., $10-20 for 30-day supply without insurance).[1]
When did patents expire, and who makes them?
Celexa's key patents expired in 2004 (Forest Laboratories, now Allergan). Lexapro's main patent expired in 2012 (also Forest), with pediatric exclusivity adding six months. Generic versions are produced by multiple manufacturers like Teva, Mylan, and Lupin. No active major patents block generics for either.[4]
Sources:
[1] FDA Labels: Celexa vs. Lexapro
[2] PubMed: Comparative efficacy review
[3] FDA QT Warnings
[4] DrugPatentWatch.com